Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Direct oral anticoagulants (DOACs) like edoxaban are crucial for preventing thromboembolic events in atrial fibrillation (AF).
• Bleeding is a primary concern with anticoagulants, necessitating an understanding of their effects on hemostasis beyond coagulation.
• Edoxaban's impact on platelet function, a key component of hemostasis, requires investigation.

Purpose of the Study:

• To investigate the in vitro effect of edoxaban on platelet aggregation in patients with non-valvular atrial fibrillation (AF).
• To assess whether edoxaban influences thrombin-induced platelet aggregation.

Main Methods:

• Light transmittance platelet aggregation (LTA) was measured in 20 AF patients treated with edoxaban.
• Platelet aggregation was assessed using 100 nmol/L γ-thrombin at baseline and 2 hours post-edoxaban administration.
• Subgroup analyses were conducted to evaluate effects across various clinical factors.

Main Results:

• Thrombin-induced platelet aggregation was significantly reduced 2 hours after edoxaban intake compared to baseline (27.25% ± 30.8% vs. 60.35% ± 33.3%).
• Subgroup analyses revealed consistent findings across different comorbidities, ages, dosages, liver/kidney functions, and concomitant treatments, indicating no significant heterogeneity.

Conclusions:

• Edoxaban significantly reduces thrombin-induced platelet aggregation in patients with non-valvular AF.
• These findings suggest that edoxaban may influence platelet function, potentially impacting bleeding risk in AF patients.